课题基金 / 基金详情

Drug Development

Drug Development
药物开发
批准号：
8330550
负责人：
KELVIN W. GEE
金额：
$36.91万
依托单位：
UNIVERSITY OF COLORADO DENVER
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
项目状态：
已结题
起止时间：
2011-09-21 至 2016-08-31
来源：
https://reporter.nih.gov/project-details/8330550
关键词：
Animal ModelAntipsychotic AgentsBiological AssayClinical TrialsDopamine D2 ReceptorDrug FormulationsHaloperidolHumanInstructionInvestigationModelingNeurocognitive DeficitNicotinic ReceptorsPatientsPersonsPharmaceutical PreparationsPharmacotherapyPhasePhase II Clinical TrialsPlasmaRattusSchizophreniaSimulateSmoking BehaviorSymptomsUrineWorkalpha-bungarotoxin receptorbehavioral pharmacologycigarette smokingcognitive functiondesigndisabilitydrug developmentimprovedpre-clinicalpreclinical studypsychosocialreceptor functionresearch study

项目摘要

项目成果

KELVIN W. GEE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
UCI-40083, a selective positive allosteric modulator (PAM) of the alpha7 nicotinic acetylcholine receptor (alpha7 nAChR), was designed and characterized by the team at UC Irvine. Its synthesis for the clinical trials and pre-clinical experiments in this NCDDDG Project will be peformed by medicinal chemists at Newport Scientific Inc., supervised by our team. We will work with Newport Scientific Inc. to conduct the assays and stability studies necessary for its formulation for human use. We will also work with Newport Scientific Inc. to support the assays in plasma and urine forthe Phase 1 and Phase 2 clinical trials. Because Phase 2 trials will be conducted in persons with schizophrenia who are treated with neurolepfic drugs, many of whom smoke cigarettes, the UC Irvine team will perform preclinical animal model studies to determine the effect of UCI-40083 on cognitive function in rats chronically treated with nicofine (to simulate smoking behavior) and/or haloperidol (to simulate antipsychofic treatment).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pain drugs based on nicotinic receptor subtype antagonists
  • 批准号：
    9763538
  • 项目类别：
  • 资助金额：
    $73.96万
  • 财政年份：
    2017
  • 负责人：
    KELVIN W. GEE
  • 依托单位：
    UNIVERSITY OF CALIFORNIA-IRVINE
Neurosteroids as a standard medical countermeasure for OP poisoning
  • 批准号：
    9352480
  • 项目类别：
  • 资助金额：
    $43.46万
  • 财政年份：
    2017
  • 负责人：
    KELVIN W. GEE
  • 依托单位：
    UNIVERSITY OF CALIFORNIA-IRVINE
Pain drugs based on nicotinic receptor subtype antagonists
  • 批准号：
    9238320
  • 项目类别：
  • 资助金额：
    $79.04万
  • 财政年份：
    2017
  • 负责人：
    KELVIN W. GEE
  • 依托单位：
    UNIVERSITY OF CALIFORNIA-IRVINE
Development of Dual GABAA and alpah7 Nicotinic Receptor Modulators for AD
  • 批准号：
    8132764
  • 项目类别：
  • 资助金额：
    $10.51万
  • 财政年份：
    2010
  • 负责人：
    KELVIN W. GEE
  • 依托单位：
    UNIVERSITY OF CALIFORNIA-IRVINE
海外基金